Mono PharmacareNSE:MONOPHARMA -1.79%9 Interest Coverage is 1.07 as of Sep. 2025, which is 50% below its 10-year median of 2.16. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 453 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 89.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Mono Pharmacare's
Operating Income
for the
six
months ended in Sep. 2025 was ₹17 Mil. Mono Pharmacare's Interest Expense for the
six
months ended in Sep. 2025 was ₹-16 Mil.
Mono Pharmacare's interest coverage for the quarter that ended in Sep. 2025 was 1.07.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Mono Pharmacare's Interest Coverage or its related term are showing as below:
NSE:MONOPHARMA'
s Interest Coverage Range Over the Past 10 Years
Min: 1.11 Med: 2.16 Max: 2.35
Current: 1.5
NSE:MONOPHARMA's Interest Coverage is ranked worse than 89.18% of 453
companies
in the Healthcare Providers & Services industry
Industry Median: 8
vs NSE:MONOPHARMA: 1.50
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Mono Pharmacare Interest Coverage Related Terms
Mono Pharmacare Interest Coverage Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Interest Coverage vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Interest Coverage of 1.07 as of Sep. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mono Pharmacare and its competitors. This is 50% below median its historical median of 2.16. Over the past decade, Mono Pharmacare's Interest Coverage has ranged from 1.11 to 2.35. According to the industry distribution chart, Mono Pharmacare ranks #404 out of 453 companies in the Healthcare Providers & Services industry, placing it in the top 89.2%.
Is Mono Pharmacare's Interest Coverage too high?
Mono Pharmacare's current Interest Coverage of 1.07 is 50% below median its 10-year median of 2.16. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 2.35. The Healthcare Providers & Services industry median Interest Coverage is 8.00. Mono Pharmacare's value of 1.07 is 86.6% below this industry median. Based on the distribution chart, Mono Pharmacare ranks #404 out of 453 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Interest Coverage compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #404 out of 453 companies for Interest Coverage. This places Mono Pharmacare in the lower half of its industry. The industry median Interest Coverage is 8.00. Mono Pharmacare's value of 1.07 is 86.6% below this benchmark. Historically, Mono Pharmacare's own Interest Coverage has ranged from 1.11 to 2.35 over the past decade. While the company's 10-year median is 2.16 vs. the industry median of 8.00, Mono Pharmacare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Healthcare Providers & Services company?
The median Interest Coverage among Healthcare Providers & Services companies is 8.00, based on 453 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current Interest Coverage of 1.07 is 86.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median Interest Coverage is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current Interest Coverage is 1.07, which is 50% below median its own 10-year median of 2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Interest Coverage of 1.07. The current Interest Coverage is 1.07, which is 50% below median its 10-year median of 2.16 and 86.6% below the Healthcare Providers & Services industry median of 8.00. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Interest Coverage is 1.07 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
